ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma

BACKGROUND: Many advanced hepatocellular carcinoma (HCC) patients are receiving sorafenib treatment. Sorafenib reportedly improves overall survival (OS) significantly in patients with HCC. Prediction of sorafenib response and prognosis in patients with HCC receiving sorafenib treatment are important...

Descripción completa

Detalles Bibliográficos
Autores principales: Takaya, Hiroaki, Namisaki, Tadashi, Shimozato, Naotaka, Kaji, Kosuke, Kitade, Mitsuteru, Moriya, Kei, Sato, Shinya, Kawaratani, Hideto, Akahane, Takemi, Matsumoto, Masanori, Yoshiji, Hitoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Observational Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522768/
https://www.ncbi.nlm.nih.gov/pubmed/31139312
http://dx.doi.org/10.4251/wjgo.v11.i5.424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522768/
https://www.ncbi.nlm.nih.gov/pubmed/31139312
http://dx.doi.org/10.4251/wjgo.v11.i5.424

Ejemplares similares